title: Altered fractionation of hemithorax irradiation for pleural mesothelioma and failure patterns after treatment.
abstract: Malignant pleural mesothelioma is a rare malignancy with a bleak prognosis. The role of radiotherapy has not yet been clarified. Our aim was to study the effect of altered fractionation on mesothelioma. We have treated 57 patients, 41 males and 16 females, with hemithorax irradiation with six different fractionation schedules. All the patients have been included in a combined modality program consisting of surgery followed by chemotherapy and finally by hemithorax irradiation. The radiotherapy schedules used were: I. Conventional fractionation of 20 Gy in 10 fractions over 12 days. II. Split-course radiotherapy 55 Gy in 25 fractions of 2.2 Gy over 7 weeks (a two weeks rest halfways) followed by a boost dose of 15 Gy over 8 days to the major tumour area. III. Hyperfractionation of 70 Gy over 7 weeks, 1.25 Gy BID with a 6-h interval and a 10-day rest halfways. IV. Combined hyperfractionation and hypofractionation, 35 Gy hyperfractionation in 28 fractions (1.25 Gy BID with a 6-h interval) over three weeks followed by 36 Gy hypofractionation 9 fractions of 4 Gy given every other day over 3 weeks to the major tumour areas only. V. Hypofractionation of 38.5 Gy over 15 days (9 x 3.5 Gy). VI. Combined conventional radiotherapy and hypofractionation with 20 Gy given conventionally in 10 fractions followed by 10 fractions of 3 Gy over two weeks, overall time 4 weeks. The 2-year survival rate of all patients was 21% and the 5-year survival rate 9%. Two patients are still alive more than 6 and 9 years after radiotherapy. Progression occurred after surgery in four patients, during and after chemotherapy in 22 patients and after completed radiotherapy in 29 patients. The pattern of progression was similar in each treatment group.
authors.affiliation: Department of Radiotherapy and Oncology, Helsinki University Central Hospital, Finland.
authors.forename: L R
authors.initials: LR
authors.lastname: Holsti
authors.forename: S
authors.initials: S
authors.lastname: Pyrhönen
authors.forename: M
authors.initials: M
authors.lastname: Kajanti
authors.forename: M
authors.initials: M
authors.lastname: Mäntylä
authors.forename: K
authors.initials: K
authors.lastname: Mattson
authors.forename: P
authors.initials: P
authors.lastname: Maasilta
authors.forename: L
authors.initials: L
authors.lastname: Kivisaari
mesh_terms: D000328:Adult; D000368:Aged; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D018450:Disease Progression; D018572:Disease-Free Survival; D005069:Evaluation Studies as Topic; D005260:Female; D017619:Hemibody Irradiation / Q000379:methods*; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy / Q000532:radiotherapy* / Q000601:surgery; D008875:Middle Aged; D010997:Pleural Neoplasms / Q000188:drug therapy / Q000532:radiotherapy* / Q000601:surgery; D011379:Prognosis; D011446:Prospective Studies; D011830:Radiation Effects; D011879:Radiotherapy Dosage; D015996:Survival Rate; D013909:Thorax; D017211:Treatment Failure